Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose

作者：Halperin Scott A^*; McNeil Shelly; Langley Joanne; Blatter Mark; Dionne Marc; Embree Joanne; Johnson Roehl; Latiolais Thomas; Meekison William; Noya Francisco; Senders Shelly; Zickler Paul; Johnson David R

来源：Vaccine, 2011, 29(46): 8459-8465.

DOI：10.1016/j.vaccine.2011.07.068

• Adult immunization
• Adolescent immunization
• Tetanus vaccine
• Diphtheria vaccine
• Acellular pertussis vaccine

Background: Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults.
Methods: This open-label, postmarketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of tetanus, diphtheria, and pertussis vaccine (Tdap) in adolescents and adults 5 years after a first dose.
Results: A total of 545 participants from previous Tdap vaccine studies, ranging in age from 15 to 69 years, participated in this study. Of these participants, 94.2% had at least one solicited adverse event after the booster dose such as injection-site erythema (28.6%), swelling (25.6%), or pain (87.6%) or a systemic adverse event such as myalgia (61.0%), headache (53.2%), malaise (38.2%), or fever (6.5%). These adverse events were slightly more frequent than after the initial dose. Postvaccination, 100% of participants had a tetanus antibody level >= 0.10 IU/mL and 95% had a diphtheria antibody level >= 0.10 IU/mL For pertussis, 82.1% (pertussis toxoid), 96.7% (filamentous hemagglutinin), 95.6% (pertactin), and 99.8% (fimbriae) had a postvaccination antibody threshold of >= 50 EU/mL.
Conclusion: A second dose of Tdap vaccine 5 years after the initial dose was well tolerated and immunogenic in adolescents and adults.

• 出版日期2011-10-26